A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients

详细信息    查看全文

• 作者：E. Cassinerio ; A. Roghi ; N. Orofino ; P. Pedrotti ; L. Zanaboni…
• 关键词：Thalassemia major ; Cardiac iron overload ; Liver iron overload ; Deferasirox ; Chelation therapy
• 刊名：Annals of Hematology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：94
• 期：6
• 页码：939-945
• 全文大小：383 KB
• 参考文献：1.Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J, American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging (2013) Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 128:281-08, Erratum in: Circulation 2013;128:e203View Article PubMed
  2.Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F (2013) Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson 15:38View Article PubMed Central PubMed
  3.Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD (2004) Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 103:1934-936View Article PubMed
  4.Kountouras D, Tsagarakis NJ, Fatourou E, Dalagiorgos E, Chrysanthos N, Berdoussi H, Vgontza N, Karagiorga M, Lagiandreou K, Voskaridou E, Roussou P, Diamanti-Kandarakis E, Koskinas J (2013) Liver disease in adult transfusion-dependent beta-thalassemic patients: investigating the role of iron overload and chronic HCV infection. Liver Int 33:420-27View Article PubMed
  5.Porter JB, Davis B (2002) Monitoring chelation therapy to achieve outcome in the treatment of thalassemia. Best Pract Res Clin Haematol 15:329-68View Article PubMed
  6.Wood JC (2009) History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 120:1937-939View Article PubMed Central PubMed
  7.Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennel DJ (2009) Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120:1961-968View Article PubMed Central PubMed
  8.Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171-179View Article PubMed
  9.Alpendurada F, Carpenter JP, Deac M, Kirk P, Walker JM, Porter JB, Banya W, He T, Smith GC, Pennell DJ (2010) Relation of myocardial T2* to right ventricular function in thalassaemia major. Eur Heart J 31:1648-654View Article PubMed
  10.Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107:3738-744View Article PubMed
  11.Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F (2006) A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 91:1241-243PubMed
  12.Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A (2013) Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Ann Hematol 92:211-19View Article PubMed Central PubMed
  13.Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years-follow-up. Blood 118:884-93View Article PubMed
  14.Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A (2012) Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica 97:842-48View Article PubMed Central PubMed
  15.Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A (2008) Guidelines for the Clinical Management of Thalassaemia. 2nd Edition Revised
  16.Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD (2005) MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle-cells disease patients. Blood 106:1460-465View Article PubMed Central PubMed
  17.Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell Science, OxfordView Article
  18.StataCorp (2011) Stata: Release 11. Statistical Software. College Station, TX: StataCorp LP
  19.Taher AT, Porter JB, Viprakasit V, Kattamis A, Chunca
• 作者单位：E. Cassinerio (1)
  A. Roghi (2)
  N. Orofino (1)
  P. Pedrotti (2)
  L. Zanaboni (1)
  E. Poggiali (3)
  M. Giuditta (1)
  D. Consonni (4)
  M. D. Cappellini (1) (3)
  
  1. Rare Diseases Center, Department of Medicine and Medical Specialities, “Ca-Granda-Ospedale Maggiore Policlinico Foundation IRCCS, Milan, Italy
  2. CMR Unit, Department of Cardiology, Niguarda Ca’Granda Hospital, Milan, Italy
  3. Department of Clinical Science and Community Health, University of Milan, Milan, Italy
  4. Epidemiology Unit, “Ca-Granda-Foundation IRCCS Ospedale Maggiore Policlinico, Milan, Italy
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. We evaluated by T2* cardiovascular magnetic resonance (CMR) the efficacy of DFX in preventing and removing cardiac and liver iron load and cardiac volume changes, along 5?years in adult thalassemia major (TM) patients. Twenty-three TM patients (9 males/14 women, mean age 36?±-?years) were included in this study. Repeated CMR was performed to assess myocardial and liver iron load?(baseline t0, after 2.5 years t1, after 5 years t2). Myocardial T2* values changed progressively and increased significantly between t0 and t2 (t0: 27.15?±-.58 vs t2: 36.64?±-.68, p--.0001). At baseline evaluation, a cardiac T2* value <20?ms was detected in six patients (26?%): they showed an improvement of cardiac T2* values between t0 and t1, with normal T2* levels reached in all patients at t2. In the overall population, a significant reduction of both end-diastolic and end-systolic left ventricular volumes (EDV, ESV) were detected between t0 and t2 (EDV, t0: 132?±-1?ml vs t2: 124?±-2?ml, p--.033; ESV, t0: 48?±-4?ml vs t2: 41?±-0?ml, p--.0007). A significant reduction in liver iron concentration (LIC) was detected at t1 (5.36?±-.58?mg/g dw at baseline vs 3.35?±-.68?mg/g dw at t1, p--.004). In patients with cardiac iron overload at baseline (n.6), mean cardiac T2* values doubled at t2, and mean LIC value is reduced of 29?%. After 5?years of treatment, DFX continually and significantly reduced myocardial and liver iron overload, and it prevented further iron deposition.